Could an FDA Approval Send This Game-Changing Cancer Detection Stock To a New Dimension?

Revolutionizing Cancer Detection: Mainz Biomed's (NASDAQ:MYNZ)(NASDAQ:MYNZ) Breakthrough Tests for Early Screening of Deadly Cancers

Remember the shocking news of Black Panther star Chadwick Boseman’s tragic death from colon cancer?¹

It wasn’t the fact that Boseman hid his illness from the world until his final days that stunned fans. It was because he wasn’t even 40 years old when he received the stage 3 diagnosis.

Up until that point, most people thought colon cancer only affected people aged 55 and up, but the truth is colon cancer rates are rising dramatically among young and middle-aged adults.

What’s even scarier is that over one-third of those diagnosed will die.

The good news is that colon cancer is actually one of the most preventable with proper screening and we’ve discovered an under-the-radar small-cap stock that is dedicated to saving lives by transforming at-home cancer detection.

For a small-cap stock, getting approval from the Food and Drug Administration (FDA) for a drug or a diagnostic device can be the game changer that sends its value soaring. One stock investors should be watching closely right now is Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ).

At a market cap of only $80 million, it’s a small-sized biotech company with blue sky written all over it. The company has successfully completed its pre-submission process with the FDA for its PMA pivotal clinical trial for ColoAlert in 2023. That means that FDA approval could potentially be in the near future and if that happens, it could send this company into a new dimension.

To put it in perspective, despite generating over $2 billion in revenue, Mainz Biomed’s closest rival’s inferior product pales in comparison and their nearly $12 billion market cap can’t touch their game-changing innovation.

Plus, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) boasts a stacked roster of renowned scientists and oncology experts, many of whom have an impressive track record of experience at top companies like Roche, Abbott Laboratories, PharmGenomics, Deloitte, and Danaher, just to name a few.

6 Compelling Reasons To Keep An Eye On Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ)

Commercially Ready Flagship Product: ColoAlert is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC) that’s the first DNA-based screening test for colorectal cancer that’s already approved in the EU. Now Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is currently in the process of seeking FDA approval in the US. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC, which cost patients an average of $38,469 per year.²
Significant Clinical Impact: The 5-year relative survival rate for colorectal cancer is approximately 90% if it is detected in its early stages, prior to spreading.³ In a multicentric study of 566 patients, ColoAlert showed the most accurate test results among non-invasive screening methods, with a sensitivity of 85% and a specificity of 92%.⁴The Company is currently adding mRNA biomarkers to their test which have the potential to boost its clinical performance, especially at early stages.
Large Market: It’s estimated that the cancer screening market will be worth $281.4 billion by 2027,⁵ which is more than twice the value it was last year at $115.60 billion.⁶ In particular, the global non-invasive cancer diagnostics market is projected to reach $201 billion by 2027, up from $142 billion in 2023, growing at a CAGR of 7.2%.⁷
Differentiated Commercial Model: ColoAlert is already being commercialized across Europe through a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. The Company expects to use this same model in the U.S. differentiating it from the competition, all of which follow a centralized model.
Pivotal FDA Study: Late in 2022, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) received approval from an independent Institutional Review Board (IRB) for the company’s US pivotal study to evaluate the clinical performance of ColoAlert, bringing the company closer to an FDA approval that would greatly open up the market potential for their flagship asset.
Led by Industry Experts with Significant Expertise: The Frankfurt-based company is led by a seasoned management team of global industry veterans supported by board members and scientific advisors including Heiner Dreismann, a former president and CEO at Roche Diagnostics

The Silent Killers: Colon and Pancreatic Cancer

Two of the most dangerous forms of cancer are those that afflict the colon and pancreas. One of the main problems with both of these cancers is the lack of screening options. Many cases go undetected until it is too late.

According to the American Cancer Society, about 1 in 23 men and 1 in 26 women will develop colorectal cancer during their lifetime.⁸ In Canada, it’s estimated that 1 in 16 men and 1 in 19 women will develop this type of cancer.⁹

Colon cancer is often considered a “silent” disease, meaning it usually has no symptoms. Symptoms that may occur include changes in bowel habits, abdominal pain, blood in the stool, and weight loss.

Meanwhile, pancreatic cancer is less common, as the 12th most common new cancer each year. Unfortunately, it is also the 4th leading cause of cancer deaths, after lung, colon, and breast cancers. This means that even though about 48,000 people are diagnosed each year, nearly the same number (40,000) will die from it.¹⁰

One of the biggest factors of success comes from early detection. What we know today though is that nearly half of all cancer deaths worldwide are preventable¹¹ as many cancers are caused by preventable risk factors.¹²

What Boseman’s death in particular taught us was that colorectal cancer is being diagnosed more often among young and middle-aged adults.¹³ Recent studies show that screening colonoscopies can reduce the relative risk of getting colon cancer by 52% and the risk of dying from it by 62%.¹⁴

But colonoscopies are costing patients more and more, and many are looking towards more non-invasive screening methods, much like that of ColoAlert from Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ).

Funding Pouring into the Early Detection Market

With its flagship asset ColoAlert, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) has solidified its position in a rapidly growing early detection market that’s not only becoming more and more profitable but also presenting an opportunity to save a huge amount of lives along the way.

Analysts are projecting that the cancer test market is going to get bigger and might be worth $261.34 billion by 2027. That’s more than twice as much as it was worth last year when it was $115.60 billion.¹⁵ Big biotech companies are buying up other companies to make their own products better and to use their technology.

In the colorectal screening market, the leading provider of cancer screening and diagnostic tests in the US is Exact Sciences¹⁶—which had its flagship screening asset ColoGuard approved by the FDA in 2014.¹⁷

Once that approval was issued, Exact Sciences was off to the races, growing from $400 million up to its current value of nearly $12 billion. The company also brought in over $2 billion in 2022,¹⁸ yet it’s only addressing 8% of the potential US market so far, leaving plenty of room for competition.

And that competition is coming, very, very soon…

Mainz Biomed’s (NASDAQ:MYNZ)(NASDAQ:MYNZ) flagship ColoAlert is already approved in the EU and poised to capture much of the same US market that ColoGuard has targeted. However, there’s a twist! MYNZ’s strategic rollout of ColoAlert involves changing the way the tests are sold.

So, pretty soon Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) should have the ability (they have clearly demonstrated this) to reach the majority of the US market, just like it’s successfully been rolled out in Germany, once FDA approval comes—all while EXAS is only reaching that 8% previously mentioned with its centrally distributed business method.

ColoAlert is not only less expensive, but it’s also easier to administer than ColoGuard while being much more accurate than the standard Fecal Immunochemical Test (FIT), and much, much less invasive than a colonoscopy.¹⁹

Hologic, Inc. (NASDAQ:HOLX) generated $559.3M in diagnostics revenue in Q1 2023 alone and $332M for its breast screening product.²⁰ Meanwhile, Guardant Health, Inc. (NASDAQ:GH) is also targeting early-stage colorectal, breast, and lung cancers with its product Guardant Reveal,²¹ and NanoString Technologies (NASDAQ:NSTG) with a series of its own oncology panels and assays.²²

The market is also responding by throwing $300M at Freenome²³ and $105M at Geneoscopy,²⁴ both of which are making strides in the cancer screening market.

So in comparison, at a current market cap of only $88M, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) has plenty of potential value built in that could rapidly be unlocked should the FDA open the door to the US for ColoAlert with preparations for its pivotal FDA study now underway.²⁵ The US market is clearly the crown jewel of the cancer screening market, and MYNZ is now waiting at the gates.

Looking into the space, it’s worth investigating how Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) stacks up against other cancer screening tech stocks, and their revenue from cancer screening products:

Differentiated Business Model

Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is currently selling ColoAlert in Europe by working with other labs instead of having their own lab.

The strategy involves giving ColoAlert to these labs, who can put their own name on it, and the labs buy the special kits from Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) when they need them. Then, the labs can help doctors and patients find colorectal cancer early by using ColoAlert.

DNA extraction for ColoAlert is now automated on the Thermo Scientific^TM Apex, representing an essential partnership that enables labs around the world to increase their testing capacity and optimize their resource allocation—and allowing for analyzing up to 96 samples per run, in roughly two hours.

On top of that, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is also advancing its technology, having reported positive results from its Feasibility Study evaluating its portfolio of novel mRNA biomarkers for early detection of advanced colorectal adenomas.³¹

The Pivotal FDA Study

The FDA now thinks that people should get checked by screening once every three years when they turn 45 years old.³² In order to get there, the American Cancer Society recommends two categories of tests: stool-based tests, and visual tests.³³

Among the easiest screening methods is Mainz Biomed NV’s (NASDAQ:MYNZ) (NASDAQ:MYNZ)ColoAlert, which has to-date delivered a 98% patient satisfaction rate³⁴ and delivers up to 60% fewer missed cases compared to fecal immunochemical tests (FIT).³⁵

But ColoAlert won’t be sold in the US until it receives proper FDA approval, and sure enough, MYNZ is on its way towards achieving that. Late in 2022, Mainz Biomed received approval from an independent Institutional Review Board (IRB) for the company’s US pivotal study to evaluate the clinical performance of ColoAlert, bringing Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) closer to an FDA approval that would greatly open up the market potential for their flagship asset.³⁶

ColoAlert is already approved in the EU, having achieved a new level of regulatory compliance in 2022.³⁷ The product is CE-IVD marked (complying with EU safety, health, and environmental requirements) and is transitioning to compliance with In Vitro Diagnostic Devices Regulation (IVDR). It’s commercially available in a selection of countries in the European Union.

Now there’s an international clinical trial underway evaluating over 600 patients (women or men) in the age range of 40-85 at two participating centers in Norway and two in Germany.

As well, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) has announced its pivotal ReconAAsense study examining the clinical performance of mRNA and DNA test combined with a fecal immunochemical test for early detection of advanced adenoma and colorectal cancer to enroll 15,000 subjects across the US, with results expected in 2025.³⁸

As well, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is nearing completion of enrollment in its eAArly DETECT study, which is an extension of the ColoFuture feasibility study of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert.³⁹ This study is expected to read out during 2023.

But it’s important to note that the ReconAAsense study in particular will form the basis of the data package for review by the US FDA to achieve marketing authorization.

Expert-Led Team

Leading the way for Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is a management team of industry experts with significant global expertise at top companies like Roche, Abbott Laboratories, PharmGenomics, Deloitte, and Danaher, fully equipped to bring the company and its flagship ColoAlert product toward commercial success.

Guido Baechler

CEO and Director

Baechler is a seasoned executive with 30 years of experience leading public and private life science companies, delivering sustained revenue and EBITDA growth. As the founder of Berkeley Life Science Advisors, Baechler has advised diagnostic and life science start-ups to navigate the complex challenges of the industry. His expertise spans various leadership positions, including CEO at SummerBio, where he demonstrated his exceptional leadership skills by driving innovation during CV-19. He was also the President and CEO at Singulex, Inc., raising over $180M through multiple financings, and a former Roche Molecular Diagnostics executive, where he led global program management.

Dr. Heiner Dreismann PhD

Chairman of the Board

Dr. Heiner Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and as a member of Roche’s Global Diagnostic Executive Committee. During the past five years, Dr. Dreismann served on the Board of Directors of Myriad Genetics, Inc., Med BioGene, Inc., Genenews Limited, Interpace Diagnostics and Ignyta, Inc.

William Caragol

CFO

William Caragol has over thirty years of experience working with growth stage technology companies. In 2018, he founded and is the Managing Director of Quidem LLC, a corporate strategic and financial advisory firm. Since 2015, Mr. Caragol has been Chairman of the Board of Thermomedics, Inc., a privately held medical diagnostic equipment company. Since July 2021 is on the Board of Directors of Worksport Ltd., an emerging electric vehicle company. From 2012 to 2018, Caragol was Chairman and CEO of PositiveID, a holding company that had a portfolio of bio-detection systems and molecular diagnostics products.

Dr. Moritz Eidens, PhD

CSO and Director

Dr. Eidens is a highly accomplished scientist and entrepreneur, having founded PharmGenomics GmbH in 2008, with a focus on developing innovative methodologies for the detection of genetic variants. He has since led PharmGenomics as co-CEO and CSO, overseeing the research and development of several groundbreaking products. Dr. Moritz has also managed numerous national and international consortial grant projects, working alongside leading industrial and academic partners. As a skilled fundraiser, Moritz has secured financing for PharmGenomics through multiple financing rounds with highly reputable national and international banks, including KfW in Bonn, Germany, and various business angels.

Darin Leigh

Chief Commercial Officer

Leigh is an accomplished executive with over 25 years of experience in product lifecycle management and global commercial operations across Europe, the US, and Asia. He’s held executive commercial positions at several leading life science and healthcare firms, including Abbott, Luminex, Metabolon, and CDR Health. Darin has a proven track record of building high-functioning international commercial teams and rapidly scaling unique and highly differentiated IVD products. During his time at Abbott Laboratories, he successfully launched the state-of-the-art Architect Immunochemistry system across 17 US states, generating over $100 million per year. As VP of Global Commercial Operations at Luminex, Leigh grew sales revenue from $26 million to $184 million, including a new molecular diagnostics business from $0 to $50 million in four years. Most recently, as COO at CDR Health, Leigh played a vital role in scaling testing, vaccination, and monoclonal antibody treatment services in response to CV-19 in Florida, delivering millions of dollars in new contracts.

RECAP: 6 Reasons to Remember the names Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) and ColoAlert Today!

Commercially Ready Product: ColoAlert is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC) that’s the first DNA-based screening test for colorectal cancer that’s already approved in the EU. Now Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is currently in the process of seeking FDA approval in the US.
Significant Clinical Impact: The 5-year relative survival rate for colorectal cancer is approximately 90% if it is detected in its early stages, prior to spreading.⁴⁰ In a multicentric study of 566 patients, ColoAlert showed the most accurate test results among non-invasive screening methods, with a sensitivity of 85% and a specificity of 92%.⁴¹ Further, the clinical performance of its 2.0 product, currently in feasibility analysis in the eAArly Detect study, is expected to have potentially superior clinical performance.
Large Market: It’s estimated that the cancer screening market will be worth $281.4B by 2027,⁴² which is more than twice the value it was last year at $115.60B.⁴³ In particular, the global non-invasive cancer diagnostics market is projected to reach $201B by 2027, up from $142B in 2023, growing at a CAGR of 7.2%.⁴⁴
Differentiated Commercial Model: ColoAlert is already being commercialized across Europe and in select international markets through a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility. This model will be followed in the U.S., giving the Company access to the largest diagnostic lab networks in the U.S.
Pivotal FDA Study: Late in 2022, Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) received approval from an independent Institutional Review Board (IRB) for the company’s US pivotal study to evaluate the clinical performance of ColoAlert, bringing the company closer to an FDA approval that would greatly open up the market potential for their flagship asset.
Led by Industry Experts with Significant Expertise: The Frankfurt-based company is led by a seasoned management team of global industry veterans supported by board members and scientific advisors.

With EU approval and sales already underway in that market Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) is poised for big things in the global cancer detection market, as we await the results of their FDA clinical study, due in 2025.

With these studies already underway, you can expect MYNZ and ColoAlert news flow over the next few months to come very fast, with the potential for many of the same game-changing developments and milestones witnessed in the ColoGuard story.

So stay up to date on the story, by visiting the official Mainz Biomed (NASDAQ:MYNZ)(NASDAQ:MYNZ) website to learn more and subscribe for their news as it happens.

¹https://thedacare.org/news-and-events/celebrity-colon-cancer-deaths-spotlight-screenings-as-key-to-early-detection/
² https://mainzbiomed.com/mainz-biomed-announces-irb-approval-and-initiation-of-us-pivotal-fda-clinical-study/
³ https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/detection.html
⁴ https://pubmed.ncbi.nlm.nih.gov/30336540/
⁵ https://www.marketwatch.com/press-release/cancer-screening-market-anticipated-to-reach-usd-28138528-million-by-emerging-trends-share-growth-rate-opportunities-and-market-forecast-to-2027-2023-03-05
⁶ https://www.globenewswire.com/news-release/2021/02/03/2169123/0/en/Cancer-Diagnostics-Market-Size-to-Hit-USD-261-34-Bn-by-2027.html
⁷ https://www.marketdataforecast.com/market-reports/non-invasive-cancer-diagnostics-market
⁸ https://www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html
⁹ https://cancer.ca/en/cancer-information/cancer-types/colorectal/statistics
¹⁰ https://muschealth.org/medical-services/geriatrics-and-aging/healthy-aging/pancreatic-cancer
¹¹ https://www.health.com/news/preventable-cancer-deaths#:~:text=There%20were%202.88%20million%20cancer,1.58%20million%2C%20or%2036.3%25.
¹² https://www.cnn.com/2022/08/18/health/cancer-deaths-preventable-study/index.html
¹³ https://www.deseret.com/2023/3/2/23622048/colorectal-cancer-that-took-chadwick-boseman-striking-earlier
¹⁴ https://www.npr.org/sections/health-shots/2022/05/31/1101861735/colonoscopy-cost-cancer-screening
¹⁵ https://www.globenewswire.com/news-release/2021/02/03/2169123/0/en/Cancer-Diagnostics-Market-Size-to-Hit-USD-261-34-Bn-by-2027.html
¹⁶ https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2023/Exact-Sciences-Announces-Fourth-Quarter-2022-Results/default.aspx
¹⁷ https://www.genomeweb.com/diagnostics/fda-approves-exact-sciences-cologuard-cms-issues-proposed-national-coverage
¹⁸ https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2023/Exact-Sciences-Announces-Fourth-Quarter-2022-Results/default.aspx
¹⁹ https://mainzbiomed.com/coloalert/
²⁰ https://investors.hologic.com/financials/fast-facts/default.aspx
²¹ https://guardanthealth.com/products/tests-for-patients-with-early-stage-cancer/
²² https://nanostring.com/products/ncounter-assays-panels/oncology/
²³ https://www.reuters.com/markets/us/biotechnology-firm-freenome-raises-300-million-fresh-funding-2021-12-07/
²⁴ https://www.genomeweb.com/business-news/geneoscopy-closes-105m-series-b-financing-round
²⁵ https://www.globenewswire.com/en/news-release/2022/03/31/2413485/0/en/Mainz-Biomed-Completes-Successful-Pre-Submission-Process-with-the-U-S-FDA-for-ColoAlert-s-Pivotal-Clinical-Trial.html
²⁶ https://www.globenewswire.com/news-release/2023/04/10/2643423/0/en/Mainz-Biomed-Provides-Full-Year-2022-Financial-Results.html
²⁷ https://investors.hologic.com/financials/fast-facts/default.aspx
²⁸ https://investor.exactsciences.com/investor-relations/press-releases/press-release-details/2023/Exact-Sciences-Announces-Fourth-Quarter-2022-Results/default.aspx
²⁹ https://investors.nanostring.com/news/news-details/2023/NanoString-Technologies-Releases-Fourth-Quarter-and-Full-Year-2022-Operating-Results-and-Provides-2023-Financial-Outlook/
³⁰ https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-2023-Outlook/
³¹ https://mainzbiomed.com/mainz-biomed-reports-positive-results-from-feasibility-study-evaluating-its-portfolio-of-novel-mrna-biomarkers-for-early-detection-of-advanced-colorectal-adenomas/
³² https://www.fda.gov/consumers/consumer-updates/colorectal-cancer-what-you-should-know-about-screening
³³ https://www.cancer.org/latest-news/understanding-tests-that-screen-for-colon-cancer.html
³⁴ 98% overall satisfaction with ColoAlert in Mainz Biomed’s internal customer survey.
³⁵ Comparing ColoAlert sensitivity with FITs (Gies et al. Gastroenterology 154/2018)
³⁶ https://mainzbiomed.com/mainz-biomed-announces-irb-approval-and-initiation-of-us-pivotal-fda-clinical-study/
³⁷ https://www.globenewswire.com/en/news-release/2022/06/01/2453852/0/en/Mainz-Biomed-Successfully-Completes-Conformity-Assessment-to-IVDR-Achieving-New-Level-of-EU-Regulatory-Compliance.html
³⁸ https://mainzbiomed.com/mainz-biomed-announces-irb-approval-and-initiation-of-us-pivotal-fda-clinical-study/
³⁹ https://mainzbiomed.com/mainz-biomed-enrolls-first-patient-in-eaarly-detect-study-evaluating-integration-of-novel-mrna-biomarkers-into-coloalert/
⁴⁰ https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/detection.html
⁴¹ https://pubmed.ncbi.nlm.nih.gov/30336540/
⁴² https://www.marketwatch.com/press-release/cancer-screening-market-anticipated-to-reach-usd-28138528-million-by-emerging-trends-share-growth-rate-opportunities-and-market-forecast-to-2027-2023-03-05
⁴³ https://www.globenewswire.com/news-release/2021/02/03/2169123/0/en/Cancer-Diagnostics-Market-Size-to-Hit-USD-261-34-Bn-by-2027.html
⁴⁴ https://www.marketdataforecast.com/market-reports/non-invasive-cancer-diagnostics-market

IMPORTANT NOTICE AND DISCLAIMER

This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Mainz Biomed N.V. (“MYNZ”) and its securities, Native Ads (Market Jar Media) has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Native Ads (Market Jar Media)) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.

SHARE OWNERSHIP.

The Publisher does not own any shares of any profiled company MYNZ and has no information concerning share ownership by others of in the profiled company MYNZ. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

FORWARD LOOKING STATEMENTS.

This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to MYNZ industry; (b) market opportunity; (c) MYNZ business plans and strategies; (d) services that MYNZ intends to offer; (e) MYNZ milestone projections and targets; (f) MYNZ expectations regarding receipt of approval for regulatory applications; (g) MYNZ intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) MYNZ expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute MYNZ business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) MYNZ ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) MYNZ ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) MYNZ ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of MYNZ to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) MYNZ operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact MYNZ business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing MYNZ business operations (e) MYNZ may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

INDEMNIFICATION/RELEASE OF LIABILITY.

By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

INTELLECTUAL PROPERTY.

Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.

IMPORTANT NOTICE AND DISCLAIMER

This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:

The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Mainz Biomed N.V.

SHARE OWNERSHIP

The Website Host does not own any shares of any profiled Mainz Biomed N.V. and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.

NO SECURITIES OFFERED

The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Mainz Biomed N.V. or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Mainz Biomed N.V.. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Mainz Biomed N.V.’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.

INDEMNIFICATION/RELEASE OF LIABILITY

By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

LINKS TO THIRD PARTY WEBSITES

This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.

INTELLECTUAL PROPERTY

The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.

FORWARD LOOKING INFORMATION

This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Mainz Biomed N.V. future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed N.V. industry; (b) market opportunity; (c) Mainz Biomed N.V. business plans and strategies; (d) services that Mainz Biomed N.V. intends to offer; (e) Mainz Biomed N.V. milestone projections and targets; (f) Mainz Biomed N.V. expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed N.V. intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed N.V. expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed N.V. business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed N.V. ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed N.V. ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed N.V. ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed N.V. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed N.V. operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Mainz Biomed N.V. business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed N.V. business operations (e) Mainz Biomed N.V. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.

HISTORICAL INFORMATION

Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed N.V. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed N.V. or such entities and are not necessarily indicative of future performance of Mainz Biomed N.V. or such entities.